Symic's SB-061 misses in Phase II for OA of the knee

In February, Symic Bio Inc. (Emeryville, Calif.) reported top-line data from the Phase II MODIFY2 trial in 60 patients with mild to moderate osteoarthritis (OA) of the knee showing that a single intra-articular injection of SB-061 missed the primary endpoint of reducing pain as measured by the change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain while walking (WOMAC A1) score from baseline to week four vs. placebo.

In a subgroup of patients with knee effusions, Symic said SB-061 led to a “clinically meaningful degree of improvement” on the pain endpoint vs. placebo. The company plans to report additional data from the double-blind, Estonian trial at an upcoming medical meeting...